Vir Biotechnology Reports Positive Phase 2 Results for Tobevibart and Elebsiran in Hepatitis Delta

Reuters

2025/11/10

<a href="https://laohu8.com/S/VIR">Vir Biotechnology</a> Reports Positive Phase 2 Results for Tobevibart and Elebsiran in Hepatitis Delta

Vir Biotechnology Inc. announced results from its Phase 2 SOLSTICE trial evaluating the combination of tobevibart and elebsiran for the treatment of chronic hepatitis delta $(CHD)$. Data presented at The Liver Meeting® of the American Association for the Study of Liver Diseases (AASLD) and published in the New England Journal of Medicine showed that 66% of participants receiving a monthly dose of the combination achieved undetectable hepatitis delta virus $(HDV)$ RNA at Week 48. The combination was well-tolerated, with no grade 3 or higher treatment-related adverse events and no treatment-related discontinuations reported. The ECLIPSE registrational program for the combination therapy is underway, with topline data expected in the first quarter of 2027. The combination has received Breakthrough Therapy and Fast Track designations from the U.S. Food and Drug Administration, as well as Priority Medicines and orphan drug designations from the European Medicines Agency.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vir Biotechnology Inc. published the original content used to generate this news brief on November 09, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2582581952"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2582581952\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2582581952?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-10 07:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582581952","market":"nz","top_or_hot":-1,"title":"Vir Biotechnology Reports Positive Phase 2 Results for Tobevibart and Elebsiran in Hepatitis Delta","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/VIR\">Vir Biotechnology</a> Reports Positive Phase 2 Results for Tobevibart and Elebsiran in Hepatitis Delta\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Vir Biotechnology Inc. announced results from its Phase 2 SOLSTICE trial evaluating the combination of tobevibart and elebsiran for the treatment of chronic hepatitis delta <a href=\"https://laohu8.com/S/CHD\">$(CHD)$</a>. Data presented at The Liver Meeting® of the American Association for the Study of Liver Diseases (AASLD) and published in the <a href=\"https://laohu8.com/S/NEWEN\">New England</a> Journal of Medicine showed that 66% of participants receiving a monthly dose of the combination achieved undetectable hepatitis delta virus <a href=\"https://laohu8.com/S/HDV\">$(HDV)$</a> RNA at Week 48. The combination was well-tolerated, with no grade 3 or higher treatment-related adverse events and no treatment-related discontinuations reported. The ECLIPSE registrational program for the combination therapy is underway, with topline data expected in the first quarter of 2027. The combination has received Breakthrough Therapy and <a href=\"https://laohu8.com/S/FTRK\">Fast Track</a> designations from the U.S. Food and Drug Administration, as well as Priority Medicines and orphan drug designations from the European Medicines Agency.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vir Biotechnology Inc. published the original content used to generate this news brief on November 09, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vir Biotechnology Reports Positive Phase 2 Results for Tobevibart and Elebsiran in Hepatitis Delta</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVir Biotechnology Reports Positive Phase 2 Results for Tobevibart and Elebsiran in Hepatitis Delta\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-10 07:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/VIR\">Vir Biotechnology</a> Reports Positive Phase 2 Results for Tobevibart and Elebsiran in Hepatitis Delta\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Vir Biotechnology Inc. announced results from its Phase 2 SOLSTICE trial evaluating the combination of tobevibart and elebsiran for the treatment of chronic hepatitis delta <a href=\"https://laohu8.com/S/CHD\">$(CHD)$</a>. Data presented at The Liver Meeting® of the American Association for the Study of Liver Diseases (AASLD) and published in the <a href=\"https://laohu8.com/S/NEWEN\">New England</a> Journal of Medicine showed that 66% of participants receiving a monthly dose of the combination achieved undetectable hepatitis delta virus <a href=\"https://laohu8.com/S/HDV\">$(HDV)$</a> RNA at Week 48. The combination was well-tolerated, with no grade 3 or higher treatment-related adverse events and no treatment-related discontinuations reported. The ECLIPSE registrational program for the combination therapy is underway, with topline data expected in the first quarter of 2027. The combination has received Breakthrough Therapy and <a href=\"https://laohu8.com/S/FTRK\">Fast Track</a> designations from the U.S. Food and Drug Administration, as well as Priority Medicines and orphan drug designations from the European Medicines Agency.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vir Biotechnology Inc. published the original content used to generate this news brief on November 09, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4535","symbol_name":"淡马锡持仓","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251109:nNDL6LFr4f:1","article_id":"2582581952","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2582581952","pubTimestamp":1762729801,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Vir Biotechnology Inc. announced results from its Phase 2 SOLSTICE trial evaluating the combination of tobevibart and elebsiran for the treatment of chronic hepatitis delta . Data presented at The Liver Meeting of the American Association for the Study of Liver Diseases  and published in the New England Journal of Medicine showed that 66% of participants receiving a monthly dose of the combination achieved undetectable hepatitis delta virus  RNA at Week 48. The combination was well-tolerated, with no grade 3 or higher treatment-related adverse events and no treatment-related discontinuations reported. The ECLIPSE registrational program for the combination therapy is underway, with topline data expected in the first quarter of 2027. The combination has received Breakthrough Therapy and Fast Track designations from the U.S. Food and Drug Administration, as well as Priority Medicines and orphan drug designations from the European Medicines Agency.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4535":"淡马锡持仓","BK4139":"生物科技","VIR":"Vir Biotechnology, Inc.","BK4568":"美国抗疫概念","BK4585":"ETF&股票定投概念"},"translate_title":"Vir Biotechnology报告Tobevibart和Elebsiran治疗δ型肝炎的积极2期结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VIR":0.9},"content_text":"Vir Biotechnology Reports Positive Phase 2 Results for Tobevibart and Elebsiran in Hepatitis Delta\n    \n\n        Vir Biotechnology Inc. announced results from its Phase 2 SOLSTICE trial evaluating the combination of tobevibart and elebsiran for the treatment of chronic hepatitis delta $(CHD)$. Data presented at The Liver Meeting® of the American Association for the Study of Liver Diseases (AASLD) and published in the New England Journal of Medicine showed that 66% of participants receiving a monthly dose of the combination achieved undetectable hepatitis delta virus $(HDV)$ RNA at Week 48. The combination was well-tolerated, with no grade 3 or higher treatment-related adverse events and no treatment-related discontinuations reported. The ECLIPSE registrational program for the combination therapy is underway, with topline data expected in the first quarter of 2027. The combination has received Breakthrough Therapy and Fast Track designations from the U.S. Food and Drug Administration, as well as Priority Medicines and orphan drug designations from the European Medicines Agency.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vir Biotechnology Inc. published the original content used to generate this news brief on November 09, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}